MYCOF (Noveris Health Sciences) Total Receivables: $0.00 Mil (As of Mar. 2026)


MYCOF Noveris Health Sciences Inc MYCOF
19 GF Score
Price $1.18
GF Value $0.52
Valuation Significantly Overvalued
View Full Analysis

What is Noveris Health Sciences Total Receivables?

Noveris Health Sciences MYCOF -41.05% 19 Total Receivables is $0.00 Mil as of Mar. 2026. GuruFocus rates MYCOF with a GF Score™ of 19/100 and a GF Value™ of $0.52 (Significantly Overvalued).

Noveris Health Sciences's Total Receivables for the quarter that ended in Mar. 2026 was $0.00 Mil.

Noveris Health Sciences Total Receivables Related Terms

Noveris Health Sciences Total Receivables Historical Data

* Premium members only.

The historical data trend for Noveris Health Sciences's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Noveris Health Sciences Total Receivables Chart

Noveris Health Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.16 0.27 0.12 0.04 0.00

Noveris Health Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MYCOF
19GF Score
Noveris Health Sciences Inc MYCOF
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Noveris Health Sciences Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $0.00 Mil mean?
Noveris Health Sciences (MYCOF) has a Total Receivables of $0.00 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Noveris Health Sciences and its competitors.
Is Noveris Health Sciences' Total Receivables too high?
Noveris Health Sciences' current Total Receivables is $0.00 Mil. Overall, Noveris Health Sciences has a GF Score™ of 19/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Noveris Health Sciences' Total Receivables compare to ZTS and UTHR?
Noveris Health Sciences' Total Receivables of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Noveris Health Sciences and its competitors. Noveris Health Sciences's current Total Receivables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Noveris Health Sciences stock overvalued right now?
Based on GuruFocus' analysis, Noveris Health Sciences (MYCOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.52, compared to a current price of $1.18 — trading 126.7% above its estimated fair value. The current Total Receivables is $0.00 Mil. Noveris Health Sciences' overall GF Score™ is 19/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Noveris Health Sciences (MYCOF), the current Total Receivables is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Noveris Health Sciences (MYCOF) Overvalued in 2026?

Based on GuruFocus' analysis, Noveris Health Sciences stock appears to be overvalued. The current stock price of $1.18 is trading 126.7% above its estimated GF Value™ of $0.52. GuruFocus considers Noveris Health Sciences to be Significantly Overvalued.

Key valuation signals for MYCOF:

  • Total Receivables: $0.00 Mil
  • GF Value™: $0.52 vs. price of $1.18 (126.7% above fair value)
  • GF Score™: 19/100

No single metric tells the full story. See the MYCOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Noveris Health Sciences Business Description

Other Exchanges 0NF1:GermanyNVRS:Canada
Address 1890 - 1075 West Georgia Street, Suite 810, Vancouver, BC, CAN, V6E 3C9
Noveris Health Sciences Inc is a biotech and life sciences company dedicated to developing and commercializing solutions for treating mental health problems and enhancing vitality. The company has a portfolio of patents it is seeking to commercialize, and is exploring opportunities in the stem cell industry. It is developing the next generation of medications and therapies to address mental health disorders such as nicotine addiction and post-traumatic stress disorder (PTSD).
19GF Score

Get the complete analysis for MYCOF

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.18
Price
$0.52
GF Value